Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study
Journal of Clinical Medicine · 18.10.2024 · 13 (20) · 6221
DOI: 10.3390/jcm13206221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.10.2024. Verfasst von Alicia López-Abad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Virgen de la Arrixaca Hospital, El Palmar, 30120 Murcia, Spain. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Androgen receptor-targeted agents have significantly improved the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). Prostate-specific antigen (PSA) levels are key prognostic markers, with rapid and deep reductions associated with better outcomes. This study aims to assess the association between the new PSA cut-offs and survival in mHSPC patients treated with Apalutamide.
Methods
We conducted a multicentre, retrospective analysis of mHSPC patients treated with Apalutamide between March 2021 and January 2023. Overall survival (OS) and radiographic progression-free survival (rFPS) were analyzed and stratified by the following PSA ranges: 0.2 ng/mL. Cox regression was applied to identify variables associated with OS and rPFS.
Results
Among 193 patients, 34.2% had de novo mHSPC, with the majority classified as M1b. A total of 58.2% (110) of our cohort achieved ultralow PSA levels, with 20.6% between 0.02 and 0.2 ng/mL, and 21.2% of PSA levels > 0.2 ng/mL. Most patients reached ultralow PSA within six months. Low-volume, metachronous, and M1a subgroups displayed a higher prevalence of patients reaching ultralow PSA levels. At 18 months, OS was 100% in the ultralow PSA group, 94.4% for the 0.02–0.2 ng/mL group, and 67.7% in the >0.2 ng/mL group. Similarly, rPFS at 18 months was 100%, 93.5%, and 50.7%, respectively. Cox regression revealed that both ultralow PSA levels and ISUP grade had a significant impact on OS (HR of 8.256 and 0.164, respectively). For rPFS, only ultralow PSA levels had a significant impact (HR = 0.085).
Conclusions
This real-world study of mHSPC patients treated with Apalutamide plus ADT revealed that achieving ultralow PSA levels is strongly associated with better oncological outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Virgen de la Arrixaca Hospital, El Palmar, 30120 Murcia, Spain.
- Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy.
- Department of Urology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.
- Department of Urology, Santa Lucía Hospital, 30202 Cartagena, Murcia, Spain.
ORCID-Profile: Alicia López-Abad, Miguel Ramírez Backhaus, Gerardo Server Gómez, Enrique Cao Avellaneda, María José Juan Fita, Pablo Luis Guzmán Martínez-Valls
Zitieren
APA
López-Abad, A., Belmonte, M., Ramírez Backhaus, M., Server Gómez, G., Cao Avellaneda, E., Moreno Alarcón, C., López Cubillana, P., Yago Giménez, P., de Pablos Rodríguez, P., Juan Fita, M. J., Climent Durán, M. Á., Guardiola Ruiz, I., Vidal Crespo, N., Moreno Avilés, J., Guzmán Martínez-Valls, P. L., & López González, P. Á. (2024). Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study. Journal of Clinical Medicine, 13(20), 6221. https://doi.org/10.3390/jcm13206221
Vancouver
López-Abad A, Belmonte M, Ramírez Backhaus M, Server Gómez G, Cao Avellaneda E, Moreno Alarcón C, et al. Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study. Journal of Clinical Medicine. 2024;13(20):6221. doi:10.3390/jcm13206221
BibTeX
@article{LpezAbad2024,
author = {López-Abad, Alicia and Belmonte, Mario and Ramírez Backhaus, Miguel and Server Gómez, Gerardo and Cao Avellaneda, Enrique and Moreno Alarcón, Cristóbal and López Cubillana, Pedro and Yago Giménez, Pablo and de Pablos Rodríguez, Pedro and Juan Fita, María José and Climent Durán, Miguel Ángel and Guardiola Ruiz, Iris and Vidal Crespo, Natalia and Moreno Avilés, Juan and Guzmán Martínez-Valls, Pablo Luis and López González, Pedro Ángel},
title = {Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {20},
pages = {6221},
doi = {10.3390/jcm13206221}
}
EUVIMED